- Home
- IMMX vs CATO Comparison
IMMX vs CATO Comparison
Compare IMMX & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CATO
- Stock Information
- Founded
- IMMX 2014
- CATO 1946
- Country
- IMMX United States
- CATO United States
- Employees
- IMMX N/A
- CATO N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CATO Clothing/Shoe/Accessory Stores
- Sector
- IMMX Health Care
- CATO Consumer Discretionary
- Exchange
- IMMX Nasdaq
- CATO Nasdaq
- Market Cap
- IMMX 61.1M
- CATO 59.2M
- IPO Year
- IMMX 2021
- CATO N/A
- Fundamental
- Price
- IMMX $2.65
- CATO $3.16
- Analyst Decision
- IMMX Strong Buy
- CATO
- Analyst Count
- IMMX 1
- CATO 0
- Target Price
- IMMX $7.00
- CATO N/A
- AVG Volume (30 Days)
- IMMX 137.1K
- CATO 33.4K
- Earning Date
- IMMX 08-11-2025
- CATO 08-21-2025
- Dividend Yield
- IMMX N/A
- CATO 5.45%
- EPS Growth
- IMMX N/A
- CATO N/A
- EPS
- IMMX N/A
- CATO N/A
- Revenue
- IMMX N/A
- CATO $642,949,000.00
- Revenue This Year
- IMMX N/A
- CATO N/A
- Revenue Next Year
- IMMX N/A
- CATO N/A
- P/E Ratio
- IMMX N/A
- CATO N/A
- Revenue Growth
- IMMX N/A
- CATO N/A
- 52 Week Low
- IMMX $1.26
- CATO $2.19
- 52 Week High
- IMMX $3.00
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- CATO 63.89
- Support Level
- IMMX $2.16
- CATO $2.84
- Resistance Level
- IMMX $2.80
- CATO $3.05
- Average True Range (ATR)
- IMMX 0.17
- CATO 0.16
- MACD
- IMMX 0.04
- CATO 0.02
- Stochastic Oscillator
- IMMX 80.00
- CATO 100.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.